For The Need Foundation is excited to announce its fifth annual Rocket Launch Day
LOS ANGELES, CA, UNITED STATES, January 29, 2025 / EINPresswire.com / -- For The Need Foundation (FTN) is excited to announce its fifth annual Rocket Launch Day and first in Los Angeles for children and their families experiencing homelessness, poverty, or unstable living conditions.
On Saturday, February 8th, 2025, For The Need Foundation will be hosting a Rocket Day for youth at the Rancho Santa Susana Community Center in Simi Valley from 9:50 AM to 2:00 PM PST.
At the event, children and teens get to build and launch model rockets, while learning about the importance of goal setting. . Waste Management We are so thankful that 'WM' has committed to sponsor this amazing event. By the beginning of 2025, For The Need hosted Volunteer Welcome & Training Days for new upcoming volunteers for the organization. This event introduced FTN's new expansion with two locations, their Simi Valley Location (805 Location) and their Los Angeles/Northridge Location (818 Location). The training days were a raging success. This annual event consisted of an introduction of FTN, role-based sessions, access to live-scan background checks, and lunch catered by Chic-Fil-A. A presentation was also given by retired U.S. Army veteran and dedicated leader, Bob Allinder, who shared how to be a critical volunteer and to make the most positive impact to the youth in the Bow & Arrow Mentorship Program. Each volunteer at the end left with a large smile, excited for what is to come in the new year and embraced in the FTN family.
Allie Spaccarelli, Director of FTN, emphasized the importance of volunteer contributions, stating, 'Volunteers are the heart of our organization. Through their dedication and compassion, we can create meaningful opportunities for families and youth facing difficult challenges.' Spaccarelli also shares, 'My favorite part of the event was seeing Mario and Sollas attending the training day, as they started as young Arrows in our program, and are now coming back to be volunteers to make an impact on kids just like them.'
About For the Need Foundation
Founded in 2004, FTN is a non-profit organization dedicated to empowering youth and families experiencing homelessness, poverty, and critical illness. They provide events throughout the year to teach life skills and provide a safe and fun environment where the children and teens can grow in their confidence and connect with positive influences in their community. Recognized as California's Nonprofit of the Year in 2023, FTN continues to transform lives by fostering resilience, hope, and opportunity.
Agency 32 Inc
YouTube
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
30-06-2025
- Associated Press
Vitalgen's Gene Therapy Drug VGN-R09b for Primary Parkinson's Disease Receives FDA Fast Track Designation
SHANGHAI, CHINA, June 30, 2025 / / -- Shanghai Vitalgen BioPharma Co., Ltd. ('Vitalgen') announced that its gene therapy drug, VGN-R09b, for the treatment of Primary Parkinson's Disease (PD), has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). VGN-R09b received IND approvals in China and the US in 2024, as a first-in-class recombinant adeno-associated virus (rAAV) gene therapy that targets two key pathways for the treatment of Parkinson's Disease (PD). The Phase I/II clinical trials have been ongoing in China since September, 2024, with all six patients dosed in the Phase I dose-escalation study. Safety data shows that the product is well-tolerated with no findings of VGN-R09b-related adverse events. Preliminary efficacy readouts show that VGN-R09b has a rapid onset of action, with significant gait improvements within two weeks post-treatment. The MDS-UPDRS Part III OFF scores decreased significantly after one month, with an average of 25-point improvements (approximately 50% improvements from the baseline) at six months. Overall, the Hoehn-Yahr (H-Y) scores progressively decreased, along with a reduction in oral medication dosages. The FTD indicates FDA's recognition of the clinical potential of VGN-R09b, marking an important milestone for Vitalgen's expansion into the chronic disease area, and it also represents a global breakthrough for a Chinese gene therapy company in the neurodegenerative field. Together with its FDA IND approval in July 2024, this FTD further validates VGN-R09b's global development potential and will provide expedited support for its future US clinical trials and regulatory filings. About Fast Track Designation (FTD) FTD is an FDA program designed to accelerate the development and approval of drugs that treat serious or life-threatening conditions and have the potential to address unmet medical needs. According to the performance report from the FDA's Center for Biologics Evaluation and Research (CBER), over 800 products have applied for FTD, with a success rate of approximately 68%. After receiving FTD, applicants are given the opportunity for frequent discussions with the FDA regarding their drug development plans, thereby increasing development efficiency. If the product meets certain criteria, it can qualify for accelerated approval, priority review, and rolling reviews, which can further accelerate development and market approval processes. About Parkinson's Disease (PD) Parkinson's Disease (PD) is the second most common neurodegenerative disease, with fast-growing incidences. It is projected that the global PD patient numbers will increase to more than 25 million by 2050. Current PD treatments are primarily small-molecule drugs for symptom relief. As the disease progresses, patients gradually lose response to oral medication, and significant motor complications persist despite fine-tuning the treatment regimens. There is currently no available treatment to delay disease progression or improve long-term outcomes. a: Projections for prevalence of Parkinson's disease and its driving factors in 195 countries and territories to 2050: modeling study of Global Burden of Disease Study 2021. BMJ. 2025;388:e080952. doi:10.1136/bmj-2024-080952. About Vitalgen Vitalgen was founded in March 2020 as a cell and gene therapy (CGT) company based in Shanghai, China, dedicated to translating cutting-edge CGT technologies into clinically accessible treatments for patients worldwide. With proprietary intellectual property rights covering three core CGT platforms: ViVec® (AAV manufacturing platform), ViCas® (CRISPR gene-editing platform) and ViLNP® (Lipid nanoparticle delivery platform), Vitalgen has developed a diversified portfolio of innovative CGTs targeting CNS diseases, ophthalmic conditions, metabolic and hematologic disorders, and oncology, including multiple potential First-in-Class (FIC) products. Up-to-date, Vitalgen has received multiple rounds of investment from renowned venture funds and has established CGT R&D labs and operational centers in the Zhangjiang High-tech Park and a GMP commercial production facility in the Waigaoqiao Free Trade Zone, Shanghai, China. David Wu Vitalgen BioPharma email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
26-06-2025
- Associated Press
Pentoxifylline Fails to Improve Survival in Alcohol-Associated Hepatitis with Kidney Injury
Researchers found no significant benefit in short- or long-term mortality outcomes with pentoxifylline use. CHINA, June 26, 2025 / / -- Severe alcohol-associated hepatitis (sAH) remains a highly lethal condition with limited therapeutic options. Characterized by rapid liver decompensation, sAH is often accompanied by acute kidney injury (AKI), a complication that substantially worsens prognosis. Corticosteroids are currently the only treatment shown to offer a modest short-term survival benefit in selected patients. Pentoxifylline, a phosphodiesterase inhibitor with anti-tumor necrosis factor alpha (TNF-α) properties, has been proposed as a potential alternative, especially for patients with contraindications to steroids or coexisting AKI. However, evidence supporting its efficacy has been inconsistent and regionally variable. To clarify the clinical utility of pentoxifylline in this setting, Idalsoaga et al. conducted a retrospective, multicenter registry study across 20 centers from eight countries. The study was published in eGastroenterology. The study included 525 patients diagnosed with sAH and AKI between 2009 and 2019. The primary outcome was all-cause mortality, with liver transplantation considered as a competing event. Main results include: (1) Survival rates at 90 days were 46.2% in the pentoxifylline group versus 49.8% in the control group. (2) Multivariable Cox regression showed that pentoxifylline use was not significantly associated with improved survival. (3) Key predictors of mortality were: older age, higher MELD score at admission, and requirement for renal replacement therapy. In addition, a secondary exploratory analysis focusing on patients with serum creatinine ≥1.5 mg/dL reaffirmed these findings. Again, pentoxifylline use did not improve survival at any time point, including 30, 90, or 180 days. The results of this large real-world cohort study confirm that pentoxifylline offers no mortality benefit in sAH patients with concurrent AKI. This is consistent with previous studies and meta-analyses that have cast doubt on the efficacy of pentoxifylline in alcoholic hepatitis overall. Although pentoxifylline has shown renal protective effects in animal models and other clinical contexts (e.g., diabetic nephropathy, cardiac surgery), these mechanisms may not sufficiently counteract the complex inflammatory and hemodynamic disturbances seen in sAH with AKI. The high rates of multiorgan failure and infection-related deaths in this cohort highlight the multifactorial pathogenesis of mortality in these patients. This study stands out for its large, diverse international cohort, and rigorous statistical approach. However, the retrospective design introduces inherent limitations such as missing data and potential confounding. Nearly half of the records lacked infection data, and the precise timing, dosing, and duration of pentoxifylline therapy were unavailable, which should be explored in the future. The clear absence of benefit from pentoxifylline suggests a pressing need for novel therapies in sAH, particularly for those with AKI who are often excluded from corticosteroid treatment. Potential strategies may include: (1) Targeting specific inflammatory pathways (e.g., IL-1, gut-liver axis); (2) Microbiota-modulating interventions; (3) Plasma exchange; (4) Trials of combination therapy (e.g., corticosteroids + novel agents). Moreover, early detection of renal dysfunction and proactive infection management remain critical components of supportive care. In conclusion, pentoxifylline does not improve survival in patients with sAH and AKI. These findings challenge current regional practices where pentoxifylline remains in use and underscore the need to re-evaluate its role in clinical guidelines. Future research should pivot toward novel, mechanism-based therapies to address the unmet needs of this high-risk population. *** About eGastroenterology eGastroenterology is a new, open-access, and open peer-reviewed BMJ Journal, which focuses on basic, clinical, translational, and evidence-based medicine research in all areas of gastroenterology (including hepatology, pancreatology, esophagology, and gastrointestinal surgery). eGastroenterology is now indexed by PubMed, Scopus, CAS, DOAJ, Dimensions, OpenAlex, ROAD, and COPE, with more to come! For more information, please visit: and follow us on Twitter (@eGastro_BMJ). Menghan Gao eGastroenterology +86 431 8878 2545 [email protected] Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Business Insider
20-06-2025
- Business Insider
The infected have evolved in '28 Years Later' — and they're scarier than ever
The "28 Days Later" franchise sees society collapsing after a virus escapes a lab and turns people into zombie-like killers. In "28 Years Later," while people have adapted to survive, the Rage Virus has evolved. Here's how the infected are different in the sequel. Warning: spoilers ahead for "28 Years Later." In " 28 Years Later," the Rage Virus that turned Britain post-apocalyptic in the original movie has evolved, meaning the survivors have new types of the infected to deal with. Spike (Alfie Williams), a 12-year-old boy, is the film's protagonist. He lives on the island of Lindisfarne, cut off from the mainland by the tide, which saves the community from the Rage Virus. His father, Jamie (Aaron Taylor-Johnson), takes him hunting on the mainland as a rite of passage, and Spike learns how dangerous the rest of the country has become after 28 years of the virus spreading. It isn't long before the young boy comes face-to-face with the infected. "There have been evolutions because we didn't want to just stand still with them," the film's director Danny Boyle told IGN in June, referring to the infected. "28 Years Later" introduces "Slow Lows" and "Alphas." On the mainland, Jamie constantly reminds Spike to be vigilant of the infected, and explains that there are "Slow Lows" who crawl on the ground eating bugs. Slow lows are more bloated than the original infected, and their skin is pale and mottled. While they're easier to kill from a distance, their loud screams draw attention. Interestingly, Jamie chooses not to kill one of the Slow Lows when he realizes she's a little girl, and she flees into the undergrowth when he lets her go. But the Slow Lows pale in comparison to the "Alphas," who are much bigger and stronger than the other infected. One Alpha, who is nicknamed Samson (Chi Lewis-Parry), shows off his brute strength by ripping a soldier's head off along with his spine with his bare hands. The Alphas can also withstand getting struck by several arrows without dying, although they can be killed by the large flaming javelins used by the guards on the Lindisfarne gate. Jamie tells Spike that in specific people, the Rage Virus acts like bodybuilding steroids, which appears to make them invulnerable to minor injuries. The Alphas make things difficult for Spike and his mother, Isla (Jodie Comer), when they go looking for a mysterious doctor on the mainland and come across one in the ruins of an old train. Knowing they can't kill an Alpha cranks up the terror in a nail-biting chase sequence.
